Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-202) as Adjunctive Therapy in Patients With Major Depressive Disorder
WALTHAM, Mass., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the enrollment of the first patient in a Phase 2b clinical trial of seltorexant (MIN-202) as adjunctive therapy to antidepressants in adult patients with major depressive disorder (MDD) who have responded inadequately to antidepressant therapy.
The primary objectives of this multi-center, double-blind, randomized, parallel group, placebo-controlled, adaptive-dose finding study are:
- to assess the dose-response relationship and antidepressant effects of up to three doses of seltorexant; and
- to assess the safety and tolerability of seltorexant compared to placebo as described in clinicaltrials.gov: NCT03227224.
"An important differentiator of seltorexant is its specificity for the orexin 2 receptor subtype, which is known to have a key role in controlling brain structures and pathways involved in mood and insomnia," said Dr. Remy Luthringer, president and chief executive officer of Minerva. "This trial follows the observed improvements in mood in an earlier study carried out in depressed patients who received seltorexant."
The trial consists of three phases: a screening phase lasting up to four weeks, a six-week double-blind treatment phase and a two-week post-treatment follow-up phase. Approximately 280 patients are planned to be enrolled at more than 85 clinical sites in the U.S., Europe, Russia and Japan.
About Seltorexant (MIN-202)
Seltorexant is a selective orexin 2 receptor antagonist under co-development by Janssen Pharmaceutica NV and Minerva as adjunctive therapy for MDD and for the treatment of insomnia disorder. The orexin system in the brain is involved in the control of several key functions, including metabolism, stress response and wakefulness.
About Minerva Neurosciences:
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of products to treat CNS diseases. Minerva's proprietary compounds include: MIN-101, in clinical development for schizophrenia; seltorexant (MIN-202), in clinical development for insomnia and major depressive disorder (MDD); MIN-117, in clinical development for MDD; and MIN-301, in pre-clinical development for Parkinson's disease. Minerva's common stock is listed on the NASDAQ Global Market under the symbol "NERV." For more information, please visit www.minervaneurosciences.com.
Forward-Looking Safe Harbor Statement
This press release contains forward-looking statements which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, reflect management's expectations as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to: the timing and results of future clinical milestones with MIN-202 in insomnia and major depressive disorder, including the timing and scope of future clinical trials and results of clinical trials with this compound; the timing and outcomes of future interactions with U.S. and foreign regulatory bodies; our agreements with Janssen related to seltorexant; our ability to successfully develop and commercialize seltorexant; the sufficiency of our current cash position to fund our operations; and management's ability to successfully achieve its goals. These forward-looking statements are based on our current expectations and may differ materially from actual results due to a variety of factors including, without limitation, whether seltorexant will advance further in the clinical trials process and whether and when, if at all, it will receive final approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies and for which indications; whether the results of future clinical trials of seltorexant, if any, will be consistent with the results of past clinical trials; whether seltorexant will be successfully marketed if approved; whether any of our therapeutic product discovery and development efforts will be successful; our ability to achieve the results contemplated by our co-development agreements; management's ability to successfully achieve its goals; our ability to raise additional capital to fund our operations on terms acceptable to us; and general economic conditions. These and other potential risks and uncertainties that could cause actual results to differ from the results predicted are more fully detailed under the caption "Risk Factors" in our filings with the Securities and Exchange Commission, including our Quarterly Report on Form 10-Q for the quarter ended June 30, 2017, filed with the Securities and Exchange Commission on August 3, 2017. Copies of reports filed with the SEC are posted on our website at www.minervaneurosciences.com . The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligation to update any forward-looking statements, except as required by law.
William B. Boni
VP, Investor Relations/
Minerva Neurosciences, Inc.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Minerva Neurosciences, Inc. via Globenewswire
Följ NASDAQ OMX
Abonnera på våra pressmeddelanden.
Senaste pressmeddelandena från NASDAQ OMX
Merus to Report Full Year 2017 Financial Results and Corporate Developments on April 26, 201819.4.2018 13:00 | Pressmeddelande
Conference call scheduled for Thursday, April 26, 2018, at 8:30 a.m. ET UTRECHT, The Netherlands, April 19, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that the Company will report full year 2017 financial results on Thursday, April 26, 2018. Merus' management team will host a conference call and audio webcast at 8:30 a.m. ET on Thursday, April 26, 2018, to discuss the financial results and recent clinical and corporate developments. To participate in the call, please dial (877) 260-1463 (U.S.) or (706) 643-5907 (international) and reference conference ID 6184636. A live webcast will be available on the Investors page of the Company's website, http://www.merus.nl. An archived webcast replay will be available for 90 days. About Merus N.V. Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeut
SEMAFO: Construction of Boungou Mine 91% Complete19.4.2018 13:00 | Pressmeddelande
Commissioning Advancing to Plan MONTREAL, April 19, 2018 (GLOBE NEWSWIRE) -- SEMAFO Inc. (TSX:SMF) (OMX:SMF) announced that construction of the Boungou Mine in Burkina Faso is 91% complete, and commissioning activities are advancing well with 10% already completed at the end of March. Since launch of commissioning at the end of February, the crushing circuit equipment and water services have been tested and commissioned. The reclaim and grinding circuits, reagent and oxygen plants are also undergoing testing. Wet commissioning began at the end of March with the Corporation pumping water from the water storage facility to the raw water tanks for the processing plant. We are still in line to achieve our first gold pour early in the third quarter of 2018. As at March 31, 2018, the following milestones had been reached: Development on budget with US$194 million of the US$231 million capital expenditure incurred Construction of the mine 91% complete Completion of 98% of structural steel and
Standard Lithium Completes Successful Gravity Geophysical Survey at Cadiz Dry Lake, California Lithium Project19.4.2018 11:30 | Pressmeddelande
VANCOUVER, British Columbia, April 19, 2018 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. ("Standard Lithium" or the "Company") (TSXV:SLL) (FRA:S5L) is pleased to announce that Hasbrouck Geophysics Inc. has successfully completed a large-scale gravity geophysical survey at the Company's Cadiz Dry Lake Project, in the Mojave area of California. The Cadiz Dry Lake Property is located approximately 20 km southeast of the Company's Bristol Dry Lake Property and is currently permitted for brine extraction and processing activities. The work has defined an infilled basin with a maximum depth of just over 700 m beneath the Project area. Dr. Andy Robinson, COO and President of Standard Lithium commented: "The results from this high quality geophysical survey are very encouraging. This work has defined a closed basin with infill deposits that are known to host lithium brines, based on preliminary sampling of extraction wells operated by the permitted producer. Standard Lithium's excellent relations
ConnectWise Launches Unite, Its Cloud Monitoring, Management and Billing Solution19.4.2018 10:03 | Pressmeddelande
IT Nation Europe keynote also reveals plans for an advanced security dashboard and growing the company's international footprint LONDON, April 19, 2018 (GLOBE NEWSWIRE) -- ConnectWise CEO Arnie Bellini told an audience of more than 350 at the company's annual IT Nation Europe conference in London that ConnectWise Unite is now available to technology teams across the globe. Unite is a cloud management solution that gives technology teams the ability to manage, monitor and bill a broad range of cloud-based solutions through a single pane of glass and in their own currency. "Technology teams typically take advantage of a broad range of cloud solutions to meet their customers' unique needs. What we've done with ConnectWise Unite is give our partners the ability to access these disparate solutions from a single pane of glass and greatly simplify the complexity that comes from dealing with the growing number of solutions they use," Bellini said. He explained that connecting the ecosystem sea
D4t4 Solutions Announces Latest Celebrus Release19.4.2018 10:00 | Pressmeddelande
Celebrus Advances Customer Data Platform Leadership Further with New Product Features Latest update consolidates Celebrus as enterprise CDP of choice for banking and insurance sectors Integration with Adobe Experience Cloud augments leading digital marketing platform with streaming customer data New Audience Segmentation feature enables advanced targeting of individuals even when they have left a site or app Latest connector supports creation of Custom Audiences in Google and Facebook Hadoop capabilities extended with enhanced support for Hive open-source data warehouse SUNBURY-ON-THAMES, United Kingdom, April 19, 2018 (GLOBE NEWSWIRE) -- D4t4 Solutions Plc has announced general availability for the latest release of its leading Celebrus Customer Data Platform (CDP). Continuing its commitment to creating the industry's most advanced unified system for customer data, Version 8 Update 19 delivers a host of new features that broaden the appeal of Celebrus to enterprises focused on deepeni
Leading European Media Company De Persgroep Selects Aria Systems for Digital Transformation19.4.2018 09:08 | Pressmeddelande
Aria's cloud billing and monetization platform will manage millions of subscriptions across dozens of media properties SAN FRANCISCO and ASSE, Belgium, April 19, 2018 (GLOBE NEWSWIRE) -- Aria Systems, the leader in helping enterprises grow subscription- and usage-based revenue, today announced that De Persgroep, the leading news media publisher in the Netherlands, Belgium and Denmark, is deploying Aria's platform to enable their digital growth strategy. With Aria the company will accelerate time to market for new products, increase subscriber growth and retention, and improve the overall customer experience. Among the publications included in this digital strategy are 18 newspapers and periodicals across the portfolios of De Persgroep Publishing, De Persgroep Nederland, and Berlingske Media. De Persgroep selected Aria's cloud-based billing and monetization platform to support the subscription management processes for all news media and magazine subscriptions. The company can now manage
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum